U.S. trial

Twenty-four weeks of treatment with the exon-skipping drug eteplirsen resulted in significant increases in dystrophin production

posted on April 2, 2012 - 5:28pm
Editor's note: This story was updated on April 27, 2012, and revised April 3, 2012.

New content is being added every day. Please check back again.